Evaluation of IgE antibodies to recombinant pollen allergens (Phl p 1, Phlp 2, and Phl p 5) in a random sample of patients with specific IgE to Phleum pratense
Re. Rossi et al., Evaluation of IgE antibodies to recombinant pollen allergens (Phl p 1, Phlp 2, and Phl p 5) in a random sample of patients with specific IgE to Phleum pratense, ALLERGY, 55(2), 2000, pp. 181-184
Background: We measured specific IgE levels against the recombinant allerge
ns (RAs) rPhl p 1, rPhl p 2, and rPhl p 5 in patients allergic to grass pol
len, and examined the existence of different patterns of IgE production to
RAs. The seasonal variations of IgE levels to rPhl p 1, rPhl p 2, and rPhl
p 5 were considered, too.
Methods: Blood was taken from 276 consecutive patients with allergy to gras
s pollen diagnosed by patient history and skin prick testing. Total and spe
cific serum IgE was measured by the immunoenzymatic CAP FETA System. Eosino
phil cationic protein (ECP) and myeloperoxidase (MPO) were assessed by radi
oimmunoassay according to the instructions of the manufacturers.
Results: We observed eight different patterns of IgE production to rPhl p 1
, rPhl p 2, and rPhl p 5 in patients with specific IgE to timothy grass. A
significant difference between the values of IgE levels to timothy and the
sum of each level of specific IgE to individual RAs was found (P = 0.039, W
ilcoxon matched pairs test) in the whole population (n = 276 subjects). In
four subgroups of patients, the sum of each level of specific IgE to indivi
dual RAs was equal to the levels of specific IgE to timothy grass extract.
In one subgroup, the sum of IgE to RAs was lower than the levels of IgE to
the natural counterpart (P = 0.013). A lack of subjects in two subgroups di
d not permit comparison at all. Finally, three subjects with specific IgE t
o timothy did not show specific IgE to RAs. Out of 276 patients, blood was
taken from two different groups of subjects at different time points: Novem
ber-January and May-July, respectively. The median values were as follows:
total IgE = 139 kU/l, IgE to timothy = 10.2 kUA/l; IgE to rPhl p 1 = 3.6 kU
A/l, to rPhl p 2 = <0.35 kUA/l, and to rPhl p 5 = 1.1 kUA/l; ECP = 8.25 mu
g/l; MPO = 303.08 mu g/l (before exposure to grass pollen); total IgE = 159
kU/l, IgE to timothy = 57.2 kUA/l; IgE to rPhl p 1 = 22.1 kUA/l, to rPhl p
2 = 5.9 kUA/l, and to rPhl p 5 = 3.9 kUA/l; ECP = 16.21 mu g/l; MPO = 413.
09 mu g/l (during the pollen season). There were significant variations of
specific IgE levels between the patients exposed to pollen and the unexpose
d patients. Moreover, there were statistical differences in the IgE, ECP, a
nd MPO levels in sera before and during the pollen season P < 0.035, P < 0.
017, and P < 0.0062, respectively.
Conclusions: The results suggest that RAs allow establishment of the patien
t's IgE-reactivity profile, encourage future research, and encourage manufa
cturers to produce further RAs for precise diagnosis and substantially impr
oved immunotherapy injection of only those allergens against which signific
ant amounts of specific IgE are produced.